Streetbeat News

Stock Prices

LOW

TGT

WMT

Home Depot Inc (HD) is set to report Q3 earnings on Nov. 14, with analysts expecting $3.58 EPS and $35.66 billion in revenue. The company has beaten EPS estimates for the past 12 quarters. Analysts are cautious due to higher interest rates, inflation, and a shift in consumer spending. Stifel analyst expects a 3% decline in FY23 comparable sales for Home Depot. The consensus price target is $319.23, with an average Buy rating. Stifel has a Hold rating with a target price of $306. HD stock traded at $288.54 and is down 8.5% YTD. Other retailers like Lowe's (LOW), Target (TGT), Walmart (WMT), and Macy's (M) are also reporting earnings this week.

Portfolio Pulse from Surbhi Jain

November 13, 2023 | 5:58 pm

GTLB

GitLab shares are trading higher following BTIG's initiation of coverage on the stock with a Buy rating and a $56 price target.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:57 pm

Guardant Health's stock (GH) is trading higher following an upgrade from Raymond James, changing its rating from Market Perform to Outperform.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:56 pm

BMWYY

BYDDF

TSLA

VLKAF

Tesla Inc (NASDAQ:TSLA) is facing a decline in EV market share in China, with October 2023 deliveries down 2.6% from September, while BYD Co Ltd (OTCPK:BYDDF) saw a 5% increase. Tesla's aggressive discounts in China have affected margins, but with factory upgrades complete, the revamped Model 3 has begun deliveries. The Chinese market is focusing on AI and smart cockpits, with domestic and non-Chinese OEMs, including Volkswagen AG (OTCPK:VLKAF), Bayerische Motoren Werke AG (OTCPK:BMWYY), Toyota Motor Corp (NYSE:TM), and General Motors Co (NYSE:GM), investing in R&D. Elon Musk's new AI venture, xAI, has produced Grok, which may be integrated into Tesla vehicles to leverage their onboard computing for AI applications.

Portfolio Pulse from Surbhi Jain

November 13, 2023 | 5:46 pm

CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP) stock is trading higher despite Morgan Stanley maintaining an Underweight rating and lowering the price target from $43 to $42. RBC Capital and Needham also lowered their price targets, but Needham maintains a Buy rating. CRISPR reported Q3 losses better than expected, and the stock is trending among retail investors and short-sellers, with a high short interest of 17.72%.

Portfolio Pulse from Erica Kollmann

November 13, 2023 | 5:45 pm

SELB

Selecta Biosciences Inc (SELB) and Cartesian Therapeutics Inc have announced a reverse merger, with Selecta shareholders owning 26.9% of the new company, which will be renamed Cartesian Therapeutics. The Nasdaq ticker will change to 'RNAC' on November 14, 2023. The combined company will focus on RNA cell therapy for autoimmune diseases, with over $110 million in cash and multiple near-term catalysts expected. SELB shares are currently down 7.05% at $0.8903.

Portfolio Pulse from Vandana Singh

November 13, 2023 | 5:45 pm

NTRA

Natera, Inc. (NTRA) shares have risen following an upgrade by Raymond James from Outperform to Strong Buy, indicating a positive outlook on the stock by the firm.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:44 pm

MPWR

Oppenheimer analyst Rick Schafer has maintained an Outperform rating on Monolithic Power Systems (NASDAQ:MPWR) and increased the price target from $500 to $600.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:43 pm

ABL

ACIC

CIA

FANH

FGF

GNW

GOCO

GSHD

HIPO

RELI

ROOT

WDH

In Monday's intraday session, insurance stocks saw movement with Waterdrop, Hippo Holdings, Goosehead Insurance, Citizens, Genworth Financial, and Root experiencing gains, while Reliance Global Group, Abacus Life, Fanhua, American Coastal, GoHealth, and FG Financial Group faced declines. The movements were attributed to trading volumes and recent Q3 earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 5:40 pm

NTLA

Oppenheimer analyst Jay Olson has maintained an Outperform rating on Intellia Therapeutics (NASDAQ:NTLA) but has reduced the price target from $80 to $70.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:34 pm